SCHEMBL1926091

SCHEMBL1926091

CCCCC[N]CCCC

nearest known ligand 0.57

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
TSHR P16473 4/20 0.57
THRB P10828 1/20 0.57
MEN1 O00255 3/20 0.50
KMT2A Q03164 3/20 0.50
NAAA Q02083 1/20 0.50
DNM1 Q05193 6/20 0.42
ALDH1A1 P00352 3/20 0.42
LMNA P02545 2/20 0.42
HSD17B10 Q99714 1/20 0.42
SLC22A1 O15245 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8857482 1.00 TSHR (0.57) TSHRTHRBMEN1KMT2ANAAA
SCHEMBL4982453 1.00 TSHR (0.57) TSHRTHRBMEN1KMT2ANAAA
SCHEMBL7680901 1.00 TSHR (0.57) TSHRTHRBMEN1KMT2ANAAA
SCHEMBL8857143 1.00 TSHR (0.57) TSHRTHRBMEN1KMT2ANAAA
SCHEMBL9213355 1.00 TSHR (0.57) TSHRTHRBMEN1KMT2ANAAA
SCHEMBL9208656 1.00 TSHR (0.57) TSHRTHRBMEN1KMT2ANAAA
SCHEMBL95733 0.96 TSHR (0.61) TSHRTHRBMEN1KMT2ANAAA
SCHEMBL277225 0.96 TSHR (0.61) TSHRTHRBMEN1KMT2ANAAA
SCHEMBL7697182 0.96 TSHR (0.61) TSHRTHRBMEN1KMT2ANAAA
SCHEMBL4399689 0.96 TSHR (0.61) TSHRTHRBMEN1KMT2ANAAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 264 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111233786-B Benzene sulfonamide compound containing five-membered heterocycle and preparation method and application thereof 中国人民解放军军事科学院军事医学研究院 2021-11-26 CN claimed
CN-111233786-A Benzene sulfonamide compound containing five-membered heterocycle and preparation method and application thereof 中国人民解放军军事科学院军事医学研究院 2020-06-05 CN claimed
WO-2024137742-A1 COMPOUNDS AND COMPOSITIONS AS FGFR3 DEGRADERS AND USES THEREOF BLUEPRINT MEDICINES CORPORATION (US) 2024-06-27 WO disclosed
US-12018267-B2 Plants having increased tolerance to herbicides BASF SE (DE) 2024-06-25 US disclosed
WO-2024130095-A1 COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2024-06-20 WO disclosed
US-11992012-B2 Diaminotriazine compounds BASF SE (DE) 2024-05-28 US disclosed
EP-4370505-A1 HERBICIDAL PHENYLURACILS BASF SE (DE) 2024-05-22 EP disclosed
WO-2024103067-A1 COMPOUNDS AND COMPOSITIONS AS eIF4E INHIBITORS AND USES THEREOF RIBOMETRIX, INC. (US) 2024-05-16 WO disclosed
WO-2024103069-A1 COMPOUNDS AND COMPOSITIONS AS eIF4E INHIBITORS AND USES THEREOF RIBOMETRIX, INC. (US) 2024-05-16 WO disclosed
WO-2024086644-A1 CEREBLON LIGANDS AND USES THEREOF ONCOPIA THERAPEUTICS, INC. D/B/A/ SK LIFE SCIENCE LABS (US) 2024-04-25 WO disclosed
US-11965171-B2 Plants having increased tolerance to herbicides BASF SE (DE) 2024-04-23 US disclosed
EP-0994108-A1 PROCESS FOR PRODUCING 2-HYDROXYBENZAMIDE DERIVATIVES ZERIA PHARMACEUTICAL CO., LTD. (JP) 2000-04-19 EP disclosed
EP-0945445-A1 1,5-BENZODIAZEPINE DERIVATIVES ZERIA PHARMACEUTICAL CO., LTD. (JP) 1999-09-29 EP disclosed
US-5688823-A ANTILIPEMIC AGENTS, ANTIGLYCEMIC AGENTS, OBESITY, GLUCOSE TOLERANCE INSUFFICIENCY, INSULIN RESISTANCE AND DIABETIC COMPLICATIONS SANKYO COMPANY, LIMITED (JP) 1997-11-18 US disclosed
US-5578620-A TREATMENT OF DIABETES AND HYPERLIPEMIA SANKYO COMPANY, LIMITED (JP) 1996-11-26 US disclosed
EP-0678511-A2 Thiazolidine and oxazolidine derivatives, their preparation and their medical use SANKYO COMPANY LIMITED (JP) 1995-10-25 EP disclosed
EP-0148725-B1 SULFONAMIDO-BENZAMIDE DERIVATIVES SHIONOGI & CO., LTD. (JP) 1987-05-06 EP disclosed
US-4595780-A Sulfonamido-benzamide derivatives SHIONOGI & CO., LTD. (JP) 1986-06-17 US disclosed
EP-0148725-A1 Sulfonamido-benzamide derivatives SHIONOGI & CO., LTD. (JP) 1985-07-17 EP disclosed
US-4182887-A ANTIPHLOGISTIC, ANTITHROMBOTIC BOEHRINGER INGELHEIM GMBH (DE) 1980-01-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11965171-B2 Plants having increased tolerance to herbicides CES2, PFAS, RNGTT TSHR 3097/4885THRB 3976/4885MEN1 4556/4885
US-11992012-B2 Diaminotriazine compounds DDT, DAZAP1, DDC TSHR 3261/4885THRB 3578/4885MEN1 3474/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.